Filtered By:
Infectious Disease: HIV AIDS
Countries: South Africa Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mo...
Source: Johnson and Johnson - January 18, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial
Lancet HIV. 2022 Nov;9(11):e760-e770. doi: 10.1016/S2352-3018(22)00253-3.ABSTRACTBACKGROUND: Comprehensive HIV prevention strategies have raised concerns that knowledge of interventions to reduce risk of HIV infection might mitigate an individual's perception of risk, resulting in riskier sexual behaviour. We investigated the prespecified secondary outcomes of the HPTN 071 (PopART) trial to determine whether a combination HIV prevention strategy, including universal HIV testing and treatment, changed sexual behaviour; specifically, we investigated whether there was evidence of sexual risk compensation.METHODS: HPTN 071 (Po...
Source: Herpes - November 4, 2022 Category: Infectious Diseases Authors: Ethan Wilson Deborah Donnell Timothy Skalland Sian Floyd Ayana Moore Nomtha Bell-Mandla Justin Bwalya Nkatya Kasese Rory Dunbar Kwame Shanaube Barry Kosloff Oliver Laeyendecker Yaw Agyei Graeme Hoddinott Peter Bock Sarah Fidler Richard Hayes Helen Ayles H Source Type: research

New head of U.S. aid program for HIV/AIDS vows to refocus attention on the other, ‘silent’ pandemic
On 13 June, John Nkengasong, 58, was appointed the first African-born head of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), a program that helps more than 50 countries respond to their HIV/AIDS epidemics. Nkengasong, who grew up in Cameroon and became a U.S. citizen in 2007, previously ran the Africa Centres for Disease Control and Prevention (Africa CDC). PEPFAR is credited with helping save more than 20 million lives since its inception in 2003. It had a $10.7 billion budget in 2021, more than half of it spent on HIV treatment and care. The agency has relied on an acting director since Deborah Birx...
Source: Science of Aging Knowledge Environment - July 5, 2022 Category: Geriatrics Source Type: research

Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial
CONCLUSION: The addition of GRT to routine care after first-line virologic failure in Uganda and South Africa did not improve rates of resuppression.PRIMARY FUNDING SOURCE: The President's Emergency Plan for AIDS Relief and the National Institute of Allergy and Infectious Diseases.PMID:34698502 | DOI:10.7326/M21-2229
Source: Annals of Internal Medicine - October 26, 2021 Category: Internal Medicine Authors: Mark J Siedner Mahomed-Yunus S Moosa Suzanne McCluskey Rebecca F Gilbert Selvan Pillay Isaac Aturinda Kevin Ard Winnie Muyindike Nicholas Musinguzi Godfrey Masette Melendhran Pillay Pravikrishnen Moodley Jaysingh Brijkumar Tamlyn Rautenberg Gavin George R Source Type: research

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Of...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news

TB, HIV and COVID-19: Urgent Questions as Three Epidemics Collide
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post TB, HIV and COVID-19: Urgent Questions as Three Epidemics Collide appeared first on Inter Press Service.
Source: IPS Inter Press Service - Health - March 25, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Africa Headlines Health Source Type: news

Another H.I.V. Vaccine Fails a Trial, Disappointing Researchers
After more than 30 years of research, 1.7 million people are still infected each year with the virus that causes AIDS.
Source: NYT Health - February 4, 2020 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome Vaccination and Immunization National Institute for Allergy and Infectious Disease (NIAID) Fauci, Anthony S South Africa Source Type: news

Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali
Conclusion Bioinformatics and data science training programs in developing countries necessitate incremental and collaborative strategies for their feasible and sustainable development. The progress described here covered decades of collaborative efforts centered on training and research on computationally intensive topics. These efforts laid the groundwork and platforms conducive for hosting a bioinformatics and data science training program in Mali. Training programs are perhaps best facilitated through Africa’s university systems as they are perhaps best positioned to maintain core resources during lapses in sho...
Source: Frontiers in Genetics - April 11, 2019 Category: Genetics & Stem Cells Source Type: research

Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Conclusion: Although NTD risks may be higher with dolutegravir than efavirenz, dolutegravir will lead to many fewer deaths among women, as well as fewer overall HIV transmissions. These results argue against a uniform policy of avoiding dolutegravir in women of child-bearing potential. Primary Funding Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases and Eunice Kennedy Shriver National Institute of Child Health and Human Development; Massachusetts General Hospital; and Harvard University Center for AIDS Research. PMID: 30934067 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - April 1, 2019 Category: Internal Medicine Authors: Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP Tags: Ann Intern Med Source Type: research